A Closer Look at Pfizer's Options Market Dynamics

Investors with a lot of money to spend have taken a bearish stance on Pfizer PFE.

And retail traders should know.

We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.

Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with PFE, it often means somebody knows something is about to happen.

So how do we know what these investors just did?

Today, Benzinga's options scanner spotted 16 uncommon options trades for Pfizer.

This isn't normal.

The overall sentiment of these big-money traders is split between 25% bullish and 56%, bearish.

Out of all of the special options we uncovered, 6 are puts, for a total amount of $252,431, and 10 are calls, for a total amount of $414,261.

Expected Price Movements

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $15.0 to $34.0 for Pfizer over the recent three months.

Analyzing Volume & Open Interest

In today's trading context, the average open interest for options of Pfizer stands at 9196.08, with a total volume reaching 17,307.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Pfizer, situated within the strike price corridor from $15.0 to $34.0, throughout the last 30 days.

Pfizer Option Activity Analysis: Last 30 Days

Biggest Options Spotted:

About Pfizer

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

Following our analysis of the options activities associated with Pfizer, we pivot to a closer look at the company's own performance.

Present Market Standing of Pfizer

• With a volume of 17,532,170, the price of PFE is down -0.07% at $27.4.
• RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.
• Next earnings are expected to be released in 33 days.

Professional Analyst Ratings for Pfizer

In the last month, 3 experts released ratings on this stock with an average target price of $45.0.

• Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $45.
• Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $45.
• In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $45.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Pfizer options trades with real-time alerts from Benzinga Pro.